TIXiMED Announces Expansion of Program-Related Investment from the Helmsley Charitable Trust Expanded Charitable Funding will Support Phase 1 Multiple Ascending Dose Trial and Long-Term Toxicology Studies for TIX100, a Novel Oral Therapy Targeting Beta Cell Health in Type 1 Diabetes BIRMINGHAM, Ala.--(BUSINESS WIRE)--TIXiMED, Inc., a clinical-stage pharmaceutical company developing innovative therapies for diabetes based on the breakthrough discovery of the role of TXNIP in disease...